0001213900-22-060782.txt : 20220930
0001213900-22-060782.hdr.sgml : 20220930
20220930172051
ACCESSION NUMBER: 0001213900-22-060782
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220929
FILED AS OF DATE: 20220930
DATE AS OF CHANGE: 20220930
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: THURMAN RANDY H
CENTRAL INDEX KEY: 0001204059
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39102
FILM NUMBER: 221284996
MAIL ADDRESS:
STREET 1: 222 MERCHANDISE MART PLAZA
STREET 2: SUITE 2024
CITY: CHICAGO
STATE: IL
ZIP: 60654
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: TFF Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001733413
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 824344737
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2600 VIA FORTUNA, SUITE 360
CITY: AUSTIN
STATE: TX
ZIP: 78746
BUSINESS PHONE: 737-802-1973
MAIL ADDRESS:
STREET 1: 2600 VIA FORTUNA, SUITE 360
CITY: AUSTIN
STATE: TX
ZIP: 78746
4
1
ownership.xml
X0306
4
2022-09-29
0
0001733413
TFF Pharmaceuticals, Inc.
TFFP
0001204059
THURMAN RANDY H
1751 RIVER RUN, SUITE 400
FORT WORTH
TX
76107
1
0
0
0
Common Stock
2022-09-29
4
M
0
40255
2.50
A
40255
D
Common Stock
2022-09-29
4
S
0
40255
4.29
D
0
D
Stock Options (Right to Buy)
2.50
2022-09-29
4
M
0
40255
0.000
D
2019-04-11
2029-04-11
Common Stock
40255
84670
D
The reported shares were sold in the open market in multiple transactions at prices ranging from $4.18 to $4.57. The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to TFF Pharmaceuticals, Inc., any stockholder of TFF Pharmaceuticals, Inc or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1).
The transactions reported by this Form 4 reflect the Reporting Person's exercise of options to purchase common shares pursuant to Rule 16b-3 under the Securities Exchange Act of 1934 and the Reporting Person's concurrent sale of the common shares acquired upon the exercise of the options.
/s/ Randy Thurman, by Kirk Allen Coleman, as Attorney-in-Fact
2022-09-30